Saturday, March 31, 2018 1:04:54 PM
I think we need to relax a little bit because a few people are going crazy talking this down like business is over..
Be honest, the Helpcomm financials don't look great. We do know that Helpcomm had approx. $4MM in revenues in 2017. That is pretty good! Good to see that BVTK bought a company with MM's in revenues that is active and in business. Liabilties etc don't look good. But hey, did anybody expect that? You can not buy a company for 1/3rd of it's revenue when it is debt free etc. Anybody who is going to sell right now after seeing this, should have left last October, because if this is a downfall to you, you truly do not understand what you are investing in.
I truely believe it was a good decision from BVTK to buy Helpcomm. From here on, BVTK/Helpcomm can move forward with more opportunies provided by Mr. Cellucci. They gave projected revenues of $5.1MM for 2018. Besides that, the Helpcomm team can support projects for a.o. Darkpulse. (see: link.
At the same time we see that the derivative liabilities are brought down substantially. I am not saying that it was perfect at december 31st, but they did manage to make agreements on that part. Today we know that they diluted approx. 600MM shares between december 31st, 2017 and March 30th. On January 31st BVTK sent out a tweet that they bought out a noteholder. During these weeks about 450MM shares were diluted. So yes, it could be true that note holders are bleeding out as Mr. Cellucci stated and that there is not much convertible debt left. We have to wait for the upcoming filings to see if this is true.
To conclude (IMHO): No things aren't perfect at this moment, but we can see progression. If you are reading BVTK financials like a public company that is in the market for years and has big revenues with YOY growth and low debt then you should move on. You can not compare these two. If you are "new" in the game you have to make debt to create revenues. With the projected revenues for 2018, I think we are moving forward in a positive way.
FEATURED NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM